Company intelligence / Profile preview

Kastle Therapeutics LLC

Chicago, Illinois, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company acquired KYNAMRO (mipomersen sodium), which has demonstrated consistent and sustained LDL reductions across five randomized placebo-controlled phase 3 clinical trials for treating Homozygous Familial Hypercholesterolemia (HoFH)

Therapeutic areas: Cardiovascular
Modalities: Small molecules (specifically KYNAMRO/Mipomersen sodium)
Industry: Biotech

Drug pipeline

1 asset

mipomersen

Commercial

Indications: Homozygous familial hypercholesterolemia

Partnerships

Ionis Pharmaceuticals (acquired KYNAMRO from them)

Beyond the preview

Go deeper on Kastle Therapeutics LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kastle Therapeutics LLC.

Explore the full profile